PharmAbcine Past Earnings Performance
Past criteria checks 0/6
PharmAbcine's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 51.1% per year.
Key information
-16.2%
Earnings growth rate
-8.3%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 51.1% |
| Return on equity | -85.9% |
| Net Margin | -19,004.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How PharmAbcine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 75 | -14,247 | 3,890 | 7,809 |
| 30 Sep 23 | 146 | -24,394 | 3,955 | 9,829 |
| 30 Jun 23 | 175 | -24,369 | 5,356 | 9,829 |
| 31 Mar 23 | 185 | -27,857 | 4,442 | 15,462 |
| 31 Dec 22 | 207 | -30,548 | 4,267 | 18,928 |
| 30 Sep 22 | 90 | -24,054 | 4,159 | 20,203 |
| 30 Jun 22 | 55 | -33,487 | 574 | 33,567 |
| 31 Mar 22 | 45 | -34,418 | 4,405 | 32,883 |
| 31 Dec 21 | 68 | -44,033 | 4,318 | 33,686 |
| 30 Sep 21 | 100 | -46,929 | 4,555 | 36,609 |
| 30 Jun 21 | 110 | -43,332 | 4,561 | 28,750 |
| 31 Mar 21 | 110 | -41,339 | 4,367 | 24,410 |
| 31 Dec 20 | 60 | -30,678 | 5,268 | 20,183 |
| 30 Sep 20 | 10 | -22,646 | 4,900 | 16,066 |
| 30 Jun 20 | 0 | -29,114 | 4,520 | 12,491 |
| 31 Mar 20 | 0 | -13,903 | 4,048 | 8,412 |
| 31 Dec 19 | 0 | -10,158 | 2,712 | 7,288 |
| 30 Sep 19 | 0 | -14,306 | 5,070 | 5,211 |
| 30 Jun 19 | 0 | 1,160 | 4,735 | 3,657 |
| 31 Mar 19 | 2 | -7,601 | 4,544 | 3,331 |
| 31 Dec 18 | 2 | -6,976 | 4,315 | 2,587 |
| 31 Dec 17 | 209 | -6,483 | 1,301 | 2,436 |
Quality Earnings: A208340 is currently unprofitable.
Growing Profit Margin: A208340 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A208340 is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.
Accelerating Growth: Unable to compare A208340's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A208340 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A208340 has a negative Return on Equity (-85.9%), as it is currently unprofitable.